Can a phone app tame asthma? UK pilot study tests digital platform

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Age ≥ 16 years * Utilization of asthma controller therapy: inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and/or fixed combination therapies of LABA and ICS (medium to high-dose ICS/LABA therapy) * Use of metered dose inhaler (MDI) and / or dry powder dose inhaler (DPI) list of compatible controller medications is noted in section 9.2. * FeNO ≥ 35 ppb during the baseline assessment. * Primary respiratory diagnosis of asthma * Uncontrolled, moderate-to-severe asthma. This is defined by an ACQ-5 ≥1.5 during the baseline assessment. * Current non-smoker. A 'current non-smoker' has never smoked or has quit smoking for at least 12 months. This is inclusive of all types of smoking: i.e. e-cigarettes/vaping. * Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in consent form and protocol. * Subject understands and is willing, able, and likely to comply with study procedures and restrictions * Willingness to participate in this study and to use the Aptar Digital Health technology * Willingness to share information / data with Aptar Digital Health (through informed consent) Access to technology * Access to a smartphone (requirements Android: ≥ 11 or iOS: ≥ 15) * Ability to use smartphone (smartphone usability assessment to be provided by Aptar Digital Health) * Access to the UK app store or google play store for application download. ● Access to a current email account * Access to data / Wi-Fi Exclusion Criteria * Age \< 16 years * FeNO \< 35 ppb * Known or suspected alcohol or drug abuse which in opinion of investigator could interfere with subject's proper completion of the protocol requirement * History of life-threatening asthma: Defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within last 6 months * A lower respiratory tract infection within 7 days of the screening visit ● Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other respiratory disorders including active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. * History of hypersensitivity/intolerance to any components of the study inhalers (example, lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates participation will also be excluded. * Ever received treatment with biological based therapy example, omalizumab, mepolizumab, for asthma. * Received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer * An immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Aptar Pharma, Aptar Digital Health, Voluntis, or Cohero employee.